FCPM III Services B.V. holds a concentrated book of 10 stocks worth $722.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Damora Therapeutics Inc and trimmed Dyne Therapeutics Inc. Their largest long position is Newamsterdam Pharma Co NV at 41% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2013410/holdings"
Use Arkolith to show FCPM III SERVICES B.V.'s latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
90% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as FCPM III Services B.V.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| FMR LLC | 10 / 10 | $801.2M |
| GOLDMAN SACHS GROUP INC | 10 / 10 | $163.2M |
| GEODE CAPITAL MANAGEMENT, LLC | 10 / 10 | $105.1M |
| BANK OF AMERICA CORP /DE/ | 10 / 10 | $58.6M |
| UBS Group AG | 10 / 10 | $56.2M |
| MORGAN STANLEY | 10 / 10 | $48.6M |
| MILLENNIUM MANAGEMENT LLC | 10 / 10 | $45.5M |
| MARSHALL WACE, LLP | 10 / 10 | $40.4M |
Ranked by how many of FCPM III Services B.V.'s top 10 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Newamsterdam Pharma Company ORDINARY SHARES | $294.5M | 9.20M | 40.8% | —Held | |
| 2 | Dyne Therapeutics Inc COM | $84.2M | 4.64M | 11.7% | ▼−15% Reduced · −818K sh | |
| 3 | Vor Biopharma Inc COM NEW | $73.5M | 4.12M | 10.2% | ▲+14% Added · +500K sh | |
| 4 | Engene Holdings Inc COM | $65.6M | 9.63M | 9.1% | —Held | |
| 5 | Maplight Therapeutics Inc COM | $65.6M | 3.23M | 9.1% | —Held | |
| 6 | Damora Therapeutics Inc COM NEW | $63.2M | 2.44M | 8.8% | ▲New New position | |
| 7 | Crescent Biopharma Inc. COM | $30.8M | 1.68M | 4.3% | —Held | |
| 8 | Replimune Group Inc COM | $21.5M | 2.81M | 3.0% | —Held | |
| 9 | Bicycle Therapeutics PLC SPONSORED ADS | $16.1M | 3.47M | 2.2% | —Held | |
| 10 | Engene Holdings Inc W EXP 10/31/2028 | $7.3M | 2.88M | 1.0% | —Held |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.